Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera

Filing Triggered a $4 Million Milestone Payment to Halozyme From Roche

Data From Subcutaneous MabThera Trials Presented at the American Society of Hematology Annual Meeting

Dec 08, 2012, 09:45 ET from Halozyme Therapeutics, Inc.

$countyNameToPathMap.put("sp